Zhang Y - Search Results

1

Early Initiation of Evolocumab Treatment in Chinese Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.

Zhang Y, Zhang Y, Zhang B, Chen Z, Wei Y, Chen P, Chang C, Liu G, Chen K, Ding J, Jiang Z. Zhang Y, et al. Among authors: zhang b. Clin Ther. 2022 Jun;44(6):901-912. doi: 10.1016/j.clinthera.2022.04.010. Epub 2022 May 14. Clin Ther. 2022. PMID: 35581018

2

Efficacy and Safety of Bivalirudin During Percutaneous Coronary Intervention in Chronic Total Occlusion: A Retrospective Study.

Zhang Y, Zhang Y, Chang C, Yan S, Chen Z, Zhang L, Chen K, Liu G. Zhang Y, et al. Among authors: zhang l. Clin Ther. 2021 May;43(5):844-851. doi: 10.1016/j.clinthera.2021.03.004. Epub 2021 Mar 31. Clin Ther. 2021. PMID: 33810894

3

Bivalirudin versus unfractionated heparin during percutaneous coronary intervention in high-bleeding-risk patients with acute coronary syndrome in contemporary practice.

Zhang Y, Zhang Y, Liu Z, Zhang B, Liu G, Chen K. Zhang Y, et al. Among authors: zhang b. Biomed Pharmacother. 2020 Oct;130:110758. doi: 10.1016/j.biopha.2020.110758. Epub 2020 Sep 17. Biomed Pharmacother. 2020. PMID: 34321166 Free article.

4

New application of a periodic mesoporous nanocrystal silicon-silica composite for hyperlipidemia.

Lu W, Jin H, Ding J, Zhang Y, Wu Y. Lu W, et al. Among authors: zhang y. Nanoscale Adv. 2023 Jul 31;5(16):4286-4297. doi: 10.1039/d3na00467h. eCollection 2023 Aug 8. Nanoscale Adv. 2023. PMID: 37560424 Free PMC article.

5

Functionalized Periodic Mesoporous Silica Nanoparticles for Inhibiting the Progression of Atherosclerosis by Targeting Low-Density Lipoprotein Cholesterol.

Jin H, Lu W, Zhang Y, Wu Y, Ding J, Orion IRCV, Liu C. Jin H, et al. Among authors: zhang y. Pharmaceutics. 2024 Jan 4;16(1):74. doi: 10.3390/pharmaceutics16010074. Pharmaceutics. 2024. PMID: 38258085 Free PMC article.

6

Early Addition of Evolocumab to Statin Treatment in Patients with Acute Coronary Syndrome and Multivessel Disease Undergoing Percutaneous Coronary Intervention.

Zhang Y, Zhang A, Wu Y, Zhang Y, Hu W, Chen P, Chen K, Ding J. Zhang Y, et al. Among authors: zhang a. Rev Cardiovasc Med. 2023 Sep 25;24(9):270. doi: 10.31083/j.rcm2409270. eCollection 2023 Sep. Rev Cardiovasc Med. 2023. PMID: 39076402 Free PMC article.

7

A Nomogram to Predict the Risk for MACCE within 1 Year after Discharge of Patients with NVAF and HFpEF: A Multicenter Retrospective Study.

Wu Y, Zhang Y, Jin H, Ding J. Wu Y, et al. Among authors: zhang y. Rev Cardiovasc Med. 2023 Dec 12;24(12):344. doi: 10.31083/j.rcm2412344. eCollection 2023 Dec. Rev Cardiovasc Med. 2023. PMID: 39077102 Free PMC article.

8

Performance of the heart failure risk scores in predicting 1 year mortality and short-term readmission of patients.

Bo X, Zhang Y, Liu Y, Kharbuja N, Chen L. Bo X, et al. Among authors: zhang y. ESC Heart Fail. 2023 Feb;10(1):502-517. doi: 10.1002/ehf2.14208. Epub 2022 Nov 3. ESC Heart Fail. 2023. PMID: 36325751 Free PMC article.

9

Outcomes of a transapical edge-to-edge repair system in secondary mitral regurgitation.

Jin Q, Li W, Fan J, Lin D, Wen Z, Zhang Y, Lai W, Pan W, Zhou D, Ge J. Jin Q, et al. Among authors: zhang y. J Invasive Cardiol. 2025 Jan 17. doi: 10.25270/jic/24.00234. Online ahead of print. J Invasive Cardiol. 2025. PMID: 39832271

10

Efficacy and safety of cefiderocol in the treatment of infections caused by Gram-negative bacteria: a systematic review and meta-analysis.

Huang X, Su L, Zhou W, Zhang Y, Yu F, Li C. Huang X, et al. Among authors: zhang y. J Infect Dev Ctries. 2024 Dec 30;18(12):1815-1823. doi: 10.3855/jidc.19875. J Infect Dev Ctries. 2024. PMID: 39832237 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

262,159 results

Search Page

Filters